» Articles » PMID: 31622417

Rapid and Structure-specific Cellular Uptake of Selected Steroids

Overview
Journal PLoS One
Date 2019 Oct 18
PMID 31622417
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Steroid hormones and their respective nuclear receptors are essential mediators in numerous physiologic and pathophysiologic processes, ranging from regulation of metabolism, immune function, and reproductive processes to the development of hormone-dependent cancers such as those of the breast and prostate. Because steroids must enter cells before activating nuclear receptors, understanding the mechanisms by which cellular uptake occurs is critical, yet a clear understanding of these mechanisms has been elusive. It is generally assumed that diffusion-driven uptake is similar across various steroids whereas an elevated cellular concentration is thought to reflect active uptake, but these assumptions have not been directly tested. Here we show that intact cells rapidly accumulate free steroids to markedly elevated concentrations. This effect varies widely depending on steroid structure; more lipophilic steroids reach more elevated concentrations. Strong preferences exist for 3β-OH, Δ5-steroids vs. 3-keto, Δ4-structural features and for progestogens vs. androgens. Surprisingly, steroid-structure-specific preferences do not require cell viability, implying a passive mechanism, and occur across cells derived from multiple tissue types. Physiologic relevance is suggested by structure-specific preferences in human prostate tissue compared with serum. On the other hand, the presence of serum proteins in vitro blocks much, but not all, of the passive accumulation, while still permitting a substantial amount of active accumulation for certain steroids. Our findings suggest that both passive and active uptake mechanisms make important contributions to the cellular steroid uptake process. The role of passive, lipophilicity-driven accumulation has previously been largely unappreciated, and its existence provides important context to studies on steroid transport and action both in vitro and in vivo.

Citing Articles

Effect of Essential Oil Components on the Activity of Steroidogenic Cytochrome P450.

Sharma K, Lanzilotto A, Yakubu J, Therkelsen S, Voegel C, du Toit T Biomolecules. 2024; 14(2).

PMID: 38397440 PMC: 10887332. DOI: 10.3390/biom14020203.


Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis.

Wrobel T, Sharma K, Mannella I, Oliaro-Bosso S, Nieckarz P, du Toit T Biomolecules. 2023; 13(9).

PMID: 37759751 PMC: 10526780. DOI: 10.3390/biom13091349.


Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy.

Alyamani M, Michael P, Hettel D, Thomas L, Lundy S, Berk M J Clin Invest. 2023; 133(17).

PMID: 37655657 PMC: 10471166. DOI: 10.1172/JCI171117.


Adrenal Steroids and Resistance to Hormonal Blockade of Prostate and Breast Cancer.

Michael P, Roversi G, Brown K, Sharifi N Endocrinology. 2022; 164(3).

PMID: 36580423 PMC: 10091490. DOI: 10.1210/endocr/bqac218.


Toward Realistic Dosimetry : Determining Effective Concentrations of Test Substances in Cell Culture and Their Prediction by an Mass Balance Model.

Dimitrijevic D, Fabian E, Nicol B, Funk-Weyer D, Landsiedel R Chem Res Toxicol. 2022; 35(11):1962-1973.

PMID: 36264934 PMC: 9682521. DOI: 10.1021/acs.chemrestox.2c00128.


References
1.
Steers W . 5alpha-reductase activity in the prostate. Urology. 2001; 58(6 Suppl 1):17-24; discussion 24. DOI: 10.1016/s0090-4295(01)01299-7. View

2.
Knuuttila M, Mehmood A, Maki-Jouppila J, Ryberg H, Taimen P, Knaapila J . Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Endocr Relat Cancer. 2018; 25(9):807-819. DOI: 10.1530/ERC-18-0148. View

3.
Mangelsdorf D, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K . The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6):835-9. PMC: 6159888. DOI: 10.1016/0092-8674(95)90199-x. View

4.
Sharifi N, Auchus R . Steroid biosynthesis and prostate cancer. Steroids. 2012; 77(7):719-26. DOI: 10.1016/j.steroids.2012.03.015. View

5.
Grindstad T, Richardsen E, Andersen S, Skjefstad K, Rakaee Khanehkenari M, Donnem T . Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression. Sci Rep. 2018; 8(1):11358. PMC: 6063894. DOI: 10.1038/s41598-018-29520-5. View